Early Detection: The Key to Improved Outcomes

One of the most significant claims is the ability to detect cancer at an earlier stage than known technologies. Their test can identify cancer at the stage zero, or pre-symptomatic stage, when the tumor is still "PET negative." This early detection is crucial, as it allows for more effective treatment and a higher chance of successful outcomes.

Precision Diagnostics: Identifying the Cancer Type

Olusium's technology not only detects the presence of cancer but also provides specific information about the type of cancer present. From a simple blood test, the company can determine whether the cancer is breast, ovarian, lung, or colorectal, among others. This level of precision is invaluable for oncologists, enabling them to tailor their treatment approach to the individual patient's needs.

Predicting Cancer Risk: A Proactive Approach

Another remarkable feature of Olusium's technology is its ability to serve as a prognostic test for cancer. By analyzing the growth rate of certain markers in the blood, the company can determine whether an individual is at risk of developing cancer within the next year. This information allows for proactive monitoring and early intervention, potentially preventing the development of full-blown cancer.

Bypassing the Limitations of Biopsies

Olusium's technology also addresses a significant challenge in cancer diagnosis – the limitations of tumor biopsies. The company's blood test can provide the same mutation and dysfunctional pathway readings that are typically obtained from a biopsy of the tumor tissue, without the associated risks and complications. This breakthrough is particularly important, as recent research has shown that the biopsy process can sometimes accelerate the activity of the tumor.

Detecting the Causative Marker

Unlike other liquid biopsy companies that focus on the detection of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) – which are the result of an established tumor – Olusium's' approach targets the causative marker that appears in the blood long before the tumor even forms. This early detection is the cornerstone of their technology, allowing for the identification of cancer at a much earlier stage.

The Olusium's and All-Organ Biopsy Tests

Olusium's technology comprises two main tests: the HRC (High-Risk Category) test and the All-Organ Biopsy test. The Olusium's test is a screening tool that provides a risk assessment based on a panel of markers, guiding patients on the frequency of follow-up testing. The All-Organ Biopsy test, on the other hand, can identify the primary and secondary organs affected by cancer, as well as provide information on the specific mutations and dysfunctional pathways involved.

Validating the Technology: Clinical Studies and Partnerships

Olusium's claims are not just bold statements but are backed by scientific evidence. The company has collaborated with CSIR-NIIST, which involved a blinded analysis of 6000-plus subjects. The results were impressive, with the test accurately identifying all non-cancer patients and detecting various stages of cancer, including high-risk individuals who later developed the disease.

The Importance of Early Detection

The key to Olusium's breakthrough lies in the recognition that cancer is a geometrically growing disease. A tumor that is just 1 cubic centimeter in size already contains a billion cancer cells, and this is often the stage at which cancer is detected using current methods. However, by the time a tumor reaches this size, the disease has already progressed significantly, reducing the chances of successful treatment.

Olusium's technology aims to address this challenge by detecting cancer much earlier when it is still at stage zero or pre-symptomatic stage. This early detection is crucial, as it allows for more effective treatment and a higher likelihood of successful outcomes.

The Road Ahead: Accessibility and Affordability

As Olusium continues to refine and validate its technology, the company is committed to making it more accessible and affordable for the general population. The vision is for this test to become a routine annual check-up, similar to a blood test, allowing for the early detection of cancer and the transformation of this disease into a manageable, treatable condition.

The team at Olusium is driven by the belief that if all 7 billion people on the planet were to undergo this test annually, cancer could be detected and addressed at an early stage, significantly improving survival rates and quality of life for those affected by this devastating disease.